CASR

Across TCGA pan-cancer cohorts, CASR Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated CASR data layer compared with 20 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher CASR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CASR expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

DLBC, MESO, and UCEC are the cancer types where CASR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	II,III,IV	0.172	0.949	<.001	27	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
UCEC	DFS	Median	II,III,IV	0.885	0.435	.033	8	view →
TGCT	DFS	Median	All	0.067	0.802	.001	6	view →
SARC	OS	Median	All	0.430	0.865	<.001	6	view →
STAD	DFS	Median	All	1.000	0.339	.039	5	view →
SCLC	DFS	Median	II,III,IV	0.274	0.615	.047	3	view →
SKCM	OS	Median	II,III,IV	0.888	0.822	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

CASR–DLBC (OS)

Open the DLBC breakdown →